Recombinant Nipah Virus Vaccines Protect Pigs against Challenge

Weingartl, Hana M.; Berhane, Yohannes; Caswell, Jeff; Loosmore, Sheena M.; Audonnet, Jean-Christophe; Roth, James A.; Czub, Markus

doi:10.1128/jvi.00263-06

Cited by 181 publications

(182 citation statements)

References 34 publications

Supporting

Mentioning

177

Contrasting

Order By: Relevance

“…Several investigators have studied NiV infection in pigs. 1,34,49,76,77 Pigs develop severe respiratory disease and encephalitis following NiV subcutaneous inoculation, resembling field infections. There are no reports of field or experimental HeV infections in pigs.…”

Section: The Brain Is a Major Target Of Niv Infection In Hamstersmentioning

confidence: 99%

“…47 A canarypox NiV vaccine was protective in pigs, and it restricted virus replication and nasal and pharyngeal shedding, thereby limiting the chance for spread of the virus to uninfected animals. 77 Furthermore, one report suggested that NiV F and G proteins may be involved in inducing CD8þ cytotoxic T-cell response to NiV. 76 Hamsters have been immunized with NiV G and F glycoproteins expressed in vaccinia virus recombinants that induced an immune response and prevented fatal infection.…”

Section: Antiviral Therapeutics and Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Henipavirus: A Review of Laboratory Animal Pathology

Williamson¹,

Torres-Vélez

2010

Vet Pathol

View full text Add to dashboard Cite

The genus Henipavirus contains two members-Hendra virus (HeV) and Nipah virus (NiV)-and each can cause fatal disease in humans and animals. HeV and Niv are currently classified as biosafety level 4, and NiV is classified as a category C priority pathogen. The aim of this article is to discuss the pathology of laboratory animal models of henipavirus infection and to assess their suitability as animal models for the development and testing of human therapeutics and vaccines. There has been considerable progress in the development of animal models for henipavirus disease. Suitable animal models include the golden hamster, ferrets, cats, and pigs, which develop disease resembling that observed in humans. Guinea pigs are a less reliable model for henipavirus disease, but they do develop henipavirus-induced encephalitis. Because human efficacy studies with henipaviruses are not permitted, animal studies are critical for the development of antiviral therapeutics and vaccines. Current research indicates that passive immunotherapy using monoclonal antibodies is protective of ferrets against NiV infection and that passive immunotherapy using NiV antibodies protects hamsters from HeV. Recombinant vaccines have been used to protect cats and pigs against NiV infection. Ribavirin and 6-aza-uridine were able to delay but not prevent NiV-induced mortality in hamsters. Further research is needed to develop a model and therapy for late-onset henipavirus encephalitis.

show abstract

Section: The Brain Is a Major Target Of Niv Infection In Hamstersmentioning

confidence: 99%

Section: Antiviral Therapeutics and Vaccinesmentioning

confidence: 99%

Henipavirus: A Review of Laboratory Animal Pathology

Williamson¹,

Torres-Vélez

2010

Vet Pathol

View full text Add to dashboard Cite

show abstract

“…36 ALVAC Canary pox vectored Nipah F and G vaccine appears to be a promising vaccine for swine and has potential as a vaccine for humans. 37 Cholesterol group is added to HRC peptides against Nipah virus targets to enhance their antiviral effect. These peptides are active to the membrane where fusion occurs and dramatically increases their antiviral effect because of increased ability to penetrate CNS.…”

Section: Controlling Infection In Health-care Settingsmentioning

confidence: 99%

Nipah Virus: A Public Health Concern

Siddique

Fardows²,

Farhana

et al. 2016

J Enam Med Col

View full text Add to dashboard Cite

show abstract

“…Moreover, this group demonstrated that the naïve animals were also protected by passive transfer of hyperimmune serum prior to challenge (Guillaume et al, 2004). An important advance was next the development of a recombinant vaccine protecting pigs against NiV challenge (Weingartl et al, 2006). The Canarypox virus expressing NiV glycoproteins was shown to be very efficient in pigs and may have a real socio-economic interest in the case of new NiV outbreaks.…”

Section: Vaccines and Treatmentsmentioning

confidence: 99%